Equities

Medipharm Labs Corp

Medipharm Labs Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.07
  • Today's Change0.00 / 0.00%
  • Shares traded35.22k
  • 1 Year change-6.67%
  • Beta0.8885
Data delayed at least 15 minutes, as of Sep 20 2024 17:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Medipharm Labs Corp share price to rise to 0.10 in the next year from the last price of 0.07.
High42.9%0.10
Med42.9%0.10
Low42.9%0.10

Earnings history & estimates in CAD

On Aug 14, 2024, Medipharm Labs Corp reported 2nd quarter 2024 losses of -0.01 per share. This result was in line with the consensus of the 2 analysts following the company and was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate0.00%
Medipharm Labs Corp reported annual 2023 losses of -0.04 per share on Mar 27, 2024.
Average growth rate+55.93%
More ▼

Revenue history & estimates in CAD

MediPharm Labs Corp. had 2nd quarter 2024 revenues of 10.35m. This bettered the 10.26m consensus of the 2 analysts covering the company. This was 77.14% above the prior year's 2nd quarter results.
Average growth rate+2.26%
MediPharm Labs Corp. had revenues for the full year 2023 of 33.06m. This was 49.49% above the prior year's results.
Average growth rate-15.12%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.